1.Before adjuvant chemotherapy for resectable non-mCRC patients : the use of this test has a suggestive effect on the selection of adjuvant chemotherapy regimens ;

2.Unresectable non-mCRC patients before treatment decision-making : using this test, suggesting conversion therapy or palliative treatment drugs ;

3.All patients with mCRC : use this test before comprehensive treatment, and formulate individualized treatment plans based on RAS / BRAF gene mutation and MSI status ;

4.For mCRC patients who failed standard treatment : use this test to find suitable targeted or immunotherapy drugs ;

5.All patients with clinically suspected Lynch syndrome : Lynch screening was performed using this test.

1、 The detection of RAS, BRAF, HER2 and other gene mutation status suggests the use of anti-EGFR, BRAF/MEK inhibitor, HER2 inhibitor and other targeted drugs, and also has prognostic significance for CRC patients

2、 The detection of chemotherapy-related genes such as UGT1A1 and DPYD can guide the treatment of CRC patients with irinotecan, fluorouracil, capecitabine, tegafur and other chemotherapy drugs.

3、 MSI status suggested the efficacy of immune checkpoint inhibitors.

4、 The detection of TP53 tumor suppressor gene provides a reference for the prognosis evaluation of patients and the clinical trials of drugs such as AZD1775.

5、 MSI and BRAF V600E suggest the risk of Lynch syndrome.

1. Nucleic Acid Extraction

2. Library Preparation （3.5 hours total time）

3. Sequencing

4. Auto-data Analysis

5. Report